Replies to post #219670 on Biotech Values

[ghmm]

SRPT:

As important from Adam's STAT article (missed it if was mentioned on SRPT call) is they will modify the study and go for approval on the one trial (I speculated as such on twitter on more than one occasion)!

https://www.statnews.com/2018/06/19/sarepta-gene-therapy-duchenne-early-results/

[DewDiligence]

SRPT -6%/AH on FDA clinical hold:

https://finance.yahoo.com/news/sarepta-therapeutics-announces-phase-1-203411514.html

Sarepta Therapeutics…has been notified by the Research Institute at Nationwide Children’s Hospital (the Research Institute) that they have received a letter from the Food and Drug Administration (FDA) on July 24, 2018, stating that their Phase 1/2a Duchenne Muscular Dystrophy (DMD) Micro-Dystrophin Gene Therapy Trial has been placed on clinical hold due to the presence of a trace amount of DNA fragment in research-grade third-party supplied plasmid.